58 assets in Osteosarcoma

Therapeutic assets addressing Osteosarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Osteosarcoma	Children's National Research Institute	P2	BB (65)
(+)-Vincristine Osteosarcoma	Milton S. Hershey Medical Center	P2	BB (65)
Olaparib Osteosarcoma	Fundación de investigación HM	P2	BB (64)
Cyclophosphamide Osteosarcoma	M.D. Anderson Cancer Center	P2	B (63)
Irinotecan Osteosarcoma	Milton S. Hershey Medical Center	P2	B (63)
Nivolumab Osteosarcoma	Instituto do Cancer do Estado de São Paulo	P2	B (62)
Fludarabine Osteosarcoma	M.D. Anderson Cancer Center	P2	B (60)
Nivestim Osteosarcoma	Albert Einstein College of Medicine	P3	B (60)
Palbociclib Osteosarcoma	National Cancer Institute (NCI)	P2	B (57)
PI3K/MTOR INHIBITOR LY3023414 Osteosarcoma	National Cancer Institute (NCI)	P2	B (57)
Tazemetostat Osteosarcoma	National Cancer Institute (NCI)	P2	B (57)
Vemurafenib Osteosarcoma	National Cancer Institute (NCI)	P2	CCC (55)
Cis-Diamminedichloroplatinum Ii Osteosarcoma	Innovent Biologics (Suzhou) Co. Ltd.	P1/2	CCC (54)
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- Osteosarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Cabozantinib Osteosarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Ensartinib Osteosarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Ivosidenib Osteosarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Osteosarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Lifileucel Osteosarcoma	M.D. Anderson Cancer Center	P2	CCC (53)
L-Methionine Osteosarcoma	St. Jude Children's Research Hospital	P2	CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Osteosarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Selpercatinib Osteosarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Osteosarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Ulixertinib Osteosarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Zoledronate Osteosarcoma	University of Florida	P1/2	CCC (53)
Onivyde Osteosarcoma	St. Jude Children's Research Hospital	P1/2	CCC (48)
Oxodotreotide Osteosarcoma	Fundación de investigación HM	P1/2	CCC (48)
pp65 rna lp Osteosarcoma	University of Florida	P1/2	CCC (48)
pp65/tumor mrna rna-lp Osteosarcoma	University of Florida	P1/2	CCC (48)
Sarcoma-Specific Car-T Cells Osteosarcoma	Shenzhen Geno-Immune Medical Institute	P1/2	CCC (48)
Surufatinib Osteosarcoma	Hutchmed	P1/2	CCC (48)
Talazoparib Osteosarcoma	St. Jude Children's Research Hospital	P1/2	CCC (48)
Tegavivint Osteosarcoma	Children's Oncology Group	P1/2	CCC (48)
Cobolimab Osteosarcoma	GlaxoSmithKline	P1/2	CC (45)
Dostarlimab Osteosarcoma	GlaxoSmithKline	P1/2	CC (45)
gd2-cart01 Osteosarcoma	Bambino Gesù Hospital and Research Institute	P1/2	CC (45)
Regorafenib Osteosarcoma	Institute of Mother and Child, Warsaw, Poland	P1/2	CC (45)
Silmitasertib Osteosarcoma	Milton S. Hershey Medical Center	P1/2	CC (45)
c7r-gd2.cart cells Osteosarcoma	Baylor College of Medicine	P1	CC (43)
b7-h3cart Osteosarcoma	Stanford University	P1	CC (41)
b7-h3 car t cells Osteosarcoma	St. Jude Children's Research Hospital	P1	CC (41)
Catequentinib Osteosarcoma	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	P1	CC (41)
CRX100 Osteosarcoma	BioEclipse Therapeutics	P1	CC (41)
ic9.gd2.car.il-15 t-cells Osteosarcoma	UNC Lineberger Comprehensive Cancer Center	P1	CC (41)
Iopofosine (¹³¹I) Osteosarcoma	Cellectar Biosciences, Inc.	P1	CC (41)
Marble Dust Osteosarcoma	Albert Einstein College of Medicine	P1	CC (41)
Mesna Osteosarcoma	St. Jude Children's Research Hospital	P1	CC (41)
Mozobil Osteosarcoma	Albert Einstein College of Medicine	P1	CC (41)
Pcna Inhibitor Aoh1996 Osteosarcoma	City of Hope Medical Center	P1	CC (41)
Pembrolizumab Osteosarcoma	Valo Therapeutics Oy	P1	CC (41)

Showing 1 to 50 of 58 assets

PreviousPage 1 of 2Next